SUMMARY

paracetamol

**PARACETAMOL
EVOLUGEN PHARMA
500 mg and 1,000 mg
tablets**

Inclusion on list: First listing

Medicinal product authorised on the basis of well-established use

Original French opinion adopted by the Transparency Committee on
26 June 2024

The legally binding text is the original French opinion version

Summary of opinion

Favourable opinion for reimbursement in the symptomatic treatment of mild to moderate pain and/or fever.

No clinical added value of the new forms compared to the forms already available.

This document and its bibliographic reference are available to download at www.has-sante.fr

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – June 2024

Transparency Committee's conclusions

Clinical Benefit

The Committee considers that the clinical benefit of PARACETAMOL EVOLUGEN PHARMA 500 mg and 1,000 mg (paracetamol) is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

→ Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%

Clinical Added Value

These medicinal products are a range supplement that do not provide any clinical added value (CAV V) compared to the forms already listed.